Wedbush Analysts Lower Earnings Estimates for MLTX

MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Investment analysts at Wedbush decreased their Q1 2025 EPS estimates for MoonLake Immunotherapeutics in a research note issued to investors on Wednesday, February 26th. Wedbush analyst Y. Zhong now anticipates that the company will earn ($0.76) per share for the quarter, down from their prior estimate of ($0.51). Wedbush currently has a "Strong-Buy" rating on the stock. The consensus estimate for MoonLake Immunotherapeutics' current full-year earnings is ($1.79) per share. Wedbush also issued estimates for MoonLake Immunotherapeutics' Q2 2025 earnings at ($0.81) EPS, Q3 2025 earnings at ($0.85) EPS, Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($3.31) EPS, FY2026 earnings at ($3.25) EPS, FY2027 earnings at ($2.97) EPS, FY2028 earnings at ($0.19) EPS and FY2029 earnings at $3.85 EPS.

A number of other research firms have also weighed in on MLTX. Needham & Company LLC boosted their price objective on MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. The Goldman Sachs Group lowered their price target on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating on the stock in a research report on Thursday, February 27th. Finally, HC Wainwright restated a "buy" rating and set a $100.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Thursday, February 27th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, MoonLake Immunotherapeutics currently has an average rating of "Buy" and a consensus price target of $83.20.

Remove Ads

MoonLake Immunotherapeutics Stock Up 1.5 %

Shares of MoonLake Immunotherapeutics stock traded up $0.59 during trading hours on Friday, reaching $40.30. 224,767 shares of the company's stock were exchanged, compared to its average volume of 343,255. The company has a market capitalization of $2.58 billion, a P/E ratio of -31.24 and a beta of 1.28. MoonLake Immunotherapeutics has a 1 year low of $37.55 and a 1 year high of $58.26. The business has a fifty day moving average of $46.24 and a two-hundred day moving average of $48.89.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.09).

Institutional Investors Weigh In On MoonLake Immunotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. PNC Financial Services Group Inc. raised its position in MoonLake Immunotherapeutics by 3.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 8,500 shares of the company's stock valued at $460,000 after purchasing an additional 320 shares during the period. Deutsche Bank AG raised its holdings in shares of MoonLake Immunotherapeutics by 59.8% in the 4th quarter. Deutsche Bank AG now owns 903 shares of the company's stock valued at $49,000 after buying an additional 338 shares during the period. GSA Capital Partners LLP lifted its stake in MoonLake Immunotherapeutics by 1.9% during the 3rd quarter. GSA Capital Partners LLP now owns 22,127 shares of the company's stock worth $1,116,000 after acquiring an additional 403 shares in the last quarter. Geode Capital Management LLC boosted its holdings in MoonLake Immunotherapeutics by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 58,950 shares of the company's stock valued at $3,192,000 after acquiring an additional 540 shares during the period. Finally, DnB Asset Management AS increased its stake in MoonLake Immunotherapeutics by 11.3% during the fourth quarter. DnB Asset Management AS now owns 8,356 shares of the company's stock worth $452,000 after purchasing an additional 847 shares during the period. 93.85% of the stock is owned by hedge funds and other institutional investors.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.